Working… Menu
Trial record 44 of 333 for:    DABIGATRAN

Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation (Dabi-ADP-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01352702
Recruitment Status : Terminated (Slow recruitment; Study was terminated for futility reasons)
First Posted : May 12, 2011
Last Update Posted : February 5, 2015
Information provided by (Responsible Party):
Deutsches Herzzentrum Muenchen

Brief Summary:
The aim of this study is to evaluate whether dabigatran reduces clopidogrel mediated ADP induced platelet aggregation measured by MEA as compared to phenprocoumon after a two-week treatment with either agent.

Condition or disease Intervention/treatment Phase
Coronary Heart Disease Atrial Fibrillation Acute Coronary Syndrome Atherosclerosis Drug: Dabigatran Drug: Phenprocoumon Phase 4

Detailed Description:

Oral anticoagulation with vitamin K antagonists (OAC) is the standard care for reducing stroke in patients with atrial fibrillation. Just recently the direct, competitive thrombin inhibitor dabigatran has been approved by the FDA for stroke prevention in patients with atrial fibrillation. In a large multicenter trial it was shown that dabigatran was at least as effective as Vitamin K antagonists in the prevention of stroke without an increase of major hemorrhage.

Approximately 6 % of patients who undergo coronary stenting and need DAT with aspirin and clopidogrel need in addition OAC for the reduction of cardiac, cerebral and systemic thromboembolic events5. These patients will therefore need triple therapy, a therapy which is associated with increased bleeding complications. Although phenprocoumon given solely without clopidogrel has no impact on ADP induced platelet aggregation, it has been shown that phenprocoumon significantly attenuates the antiplatelet effects of clopidogrel.

ADP induced platelet aggregation measured with multiple electrode platelet aggregometry (MEA) is a marker for the efficacy of the clopidogrel therapy and (i) a low response (AUC ≥ 468) to clopidogrel has been associated with an increase of ischemic events such as stent thrombosis and (ii) patients with an enhanced response to clopidogrel (AUC ≤ 188) have higher bleeding rates.

It is therefore crucial to evaluate whether an additional antithrombotic therapy such as dabigatran alters clopidogrel mediated ADP induced platelet aggregation. While it has been shown that intravenous administration of the direct thrombin inhibitor bivalirudin further reduces ADP induced platelet aggregation in patients on clopidogrel therapy, it is unknown whether dabigatran has also an impact on ADP induced platelet aggregation.

To evaluate the impact of dabigatran on ADP induced platelet aggregation we will randomize patients with atrial fibrillation and the need for oral anticoagulation and current clopidogrel therapy for a two-week treatment with either dabigatran or phenprocoumon and we hypothesize that dabigatran is superior to phenprocoumon in the reduction of ADP induced platelet aggregation. Patients who are not concomitantly treated with clopidogrel are being studied in a different trial with a similar study design (Dabi ADP-1).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation
Study Start Date : May 2011
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Arm Intervention/treatment
Experimental: Arm 1
Dabigatran Therapy
Drug: Dabigatran
Patients assigned to this group will receive Dabigatran
Other Name: Pradaxa

Active Comparator: Arm 2
Phenprocoumon Therapy
Drug: Phenprocoumon
Patients assigned to this group will receive Phenprocoumon
Other Name: Marcumar

Primary Outcome Measures :
  1. ADP induced platelet aggregation [ Time Frame: 2 weeks ]
    To determine whether there are differences in ADP induced platelet aggregation after 2 weeks in patients receiving dabigatran or phenprocoumon.

Secondary Outcome Measures :
  1. Platelet function tests [ Time Frame: 2 weeks ]
    ADPtest HS (MEA) , TRAP, Collagen

  2. Coagulation parameters [ Time Frame: 2 weeks ]
    aPTT, INR, Thrombin coagulation time

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Patients with atrial fibrillation and an indication for oral anticoagulation (CHA2DS2-VASc score≥ 1).
  • Current clopidogrel treatment
  • Informed, written consent by the patient or her/his legally-authorized representative for participation in the study.

Key Exclusion Criteria:

  • Age ≤18 years
  • Cardiogenic shock
  • Current therapy with dabigatran
  • Patients with a recent thromboembolic event and high thromboembolic risk requiring bridging therapy with either unfractionated heparin or LMWH
  • Contraindication for oral anticoagulation
  • Active bleeding
  • Known allergy or intolerance to the study medications: dabigatran, phenprocoumon

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01352702

Layout table for location information
Deutsches Herzzentrum Muenchen
Munich, Germany, 80636
Sponsors and Collaborators
Deutsches Herzzentrum Muenchen
Layout table for investigator information
Principal Investigator: Julinda Mehilli, MD Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen

Layout table for additonal information
Responsible Party: Deutsches Herzzentrum Muenchen Identifier: NCT01352702     History of Changes
Other Study ID Numbers: GE IDE No. A01711
2011-000504-18 ( EudraCT Number )
First Posted: May 12, 2011    Key Record Dates
Last Update Posted: February 5, 2015
Last Verified: February 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Heart Diseases
Acute Coronary Syndrome
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Arrhythmias, Cardiac
Cardiovascular Diseases
Pathologic Processes
Arterial Occlusive Diseases
Vascular Diseases
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors